Reply to Letter Regarding Article, “evidence That Links Loss of Cyclooxygenase-2 with Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated with Anti-Inflammatory Drugs”
Blerina Ahmetaj‐Shala,Nicholas S. Kirkby,Rebecca Knowles,Malak Al-Yamani,Sara Mazi,Zhen Wang,A. Tucker,Louise Mackenzie,Paul C. Armstrong,Rolf M. Nüsing,James Tomlinson,Timothy D. Warner,James Leiper,Jane A. Mitchell
DOI: https://doi.org/10.1161/circulationaha.115.017260
IF: 37.8
2015-01-01
Circulation
Abstract:HomeCirculationVol. 132, No. 17Reply to Letter Regarding Article, “Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugs” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBReply to Letter Regarding Article, “Evidence That Links Loss of Cyclooxygenase-2 With Increased Asymmetric Dimethylarginine: Novel Explanation of Cardiovascular Side Effects Associated With Anti-Inflammatory Drugs” Blerina Ahmetaj-Shala, PhD and Nicholas S. Kirkby, PhD Rebecca Knowles, MD Malak Al’Yamani, MSc and Sara Mazi, MRes Zhen Wang, PhD Arthur T. Tucker, PhD Louise S. Mackenzie, PhD Paul C.J. Armstrong, PhD Rolf M. Nüsing, PhD James A. P. Tomlinson, MD, PhD Timothy D. Warner, PhD James Leiper, PhD Jane A. Mitchell, PhD Blerina Ahmetaj-ShalaBlerina Ahmetaj-Shala Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK Search for more papers by this author and Nicholas S. KirkbyNicholas S. Kirkby Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK Search for more papers by this author Rebecca KnowlesRebecca Knowles The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK Search for more papers by this author Malak Al’YamaniMalak Al’Yamani Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK, King Fahad Cardiac Center, King Saud University, Riyadh, Saudi Arabia Search for more papers by this author and Sara MaziSara Mazi Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK, King Fahad Cardiac Center, King Saud University, Riyadh, Saudi Arabia Search for more papers by this author Zhen WangZhen Wang MRC Clinical Sciences, Imperial College London, Nitric Oxide Signalling Group, Hammersmith Hospital, London, UK Search for more papers by this author Arthur T. TuckerArthur T. Tucker The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK Search for more papers by this author Louise S. MackenzieLouise S. Mackenzie School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK Search for more papers by this author Paul C.J. ArmstrongPaul C.J. Armstrong The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK Search for more papers by this author Rolf M. NüsingRolf M. Nüsing Institute of Clinical Pharmacology, Johann Wolfgang Goethe-University, Frankfurt, Germany Search for more papers by this author James A. P. TomlinsonJames A. P. Tomlinson MRC Clinical Sciences, Imperial College London, Nitric Oxide Signalling Group, Hammersmith Hospital, London, UK Search for more papers by this author Timothy D. WarnerTimothy D. Warner The William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK Search for more papers by this author James LeiperJames Leiper MRC Clinical Sciences, Imperial College London, Nitric Oxide Signalling Group, Hammersmith Hospital, London, UK Search for more papers by this author Jane A. MitchellJane A. Mitchell Cardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College, London, UK Search for more papers by this author Originally published27 Oct 2015https://doi.org/10.1161/CIRCULATIONAHA.115.017260Circulation. 2015;132:e213–e214We thank Professor Surdacki and colleagues for their interest in our work.1 Our work published recently in Circulation shows that genetic deletion or pharmacological inhibition of cyclooxygenase-2 with nonsteroidal anti-inflammatory drugs (NSAIDs) increases plasma levels of the naturally occurring nitric oxide (NO) synthase inhibitors asymmetrical dimethylarginine (ADMA) and monomethyl-l-arginine. In light of our data, we hypothesized that ADMA may represent a biomarker and a mechanistic bridge between cyclooxygenase-2/vascular NO and cardiovascular risk, explaining the cardiovascular side effects associated with NSAIDs. The use of NSAIDs globally is a phenomenon, with billions of doses taken each year in the United States alone. They are the most commonly used over-the-counter medications and represent the first-line therapy for the majority of patients with arthritis. The risk of cardiovascular side effects with NSAIDs is relatively small but, considering the number of people taking these drugs, represents a global health problem. Furthermore, the fear and anxiety surrounding the cardiovascular risk of using NSAIDs, particularly selective inhibitors of cyclooxygenase-2, have slowed research into new drugs and virtually stopped progress in the use of these drugs to prevent cancer. For these reasons, it is vitally important that we find biomarkers, mechanisms, and treatments to protect those individuals most at risk.Our data are entirely consistent with those published by Professor Surdacki’s group2 showing elevated ADMA levels in patients with rheumatoid arthritis, who, as would be expected, were all taking NSAIDs.2 Interestingly, in their article, the levels of ADMA correlated with atherosclerosis,2 an observation that is in line with the idea that ADMA is a meaningful biomarker and mediator of cardiovascular disease. The authors rightly point out that proton pump inhibitors, now commonly coprescribed with NSAIDs, increase ADMA via an inhibitory action on one of its removal systems, dimethylarginine dimethylaminohydrolase-1.3 The idea that NSAIDs together with proton pump inhibitors might cause an additive increase in ADMA levels is concerning and should be addressed, not least because some evidence suggests that proton pump inhibitors may increase cardiovascular events in some patient groups.Professor Surdacki and colleagues also rightly point out the implications of our work for what we know pharmacologically of the powerful synergy between NO and prostacyclin on platelet function. Other recent work from our group has established that NO synergizes not only with prostacyclin but also with P2Y12 blockers such as prasugrel and clopidogrel.4 When we consider that P2Y12 blockers are among the most widely prescribed medication for people at risk of cardiovascular disease, some of whom will also be taking NSAIDs, the idea that inhibition of cyclooxygenase-2 can indirectly affect NO formation in vessels needs to be studied carefully. Our findings along with those of Professor Surdacki provide a potential biomarker to identify those individual patients at risk but also a rescue therapy in the form of l-arginine supplementation. These ideas need to be fully explored both with preclinical models such as those described in our study1 and in the form of comprehensive clinical trials.Blerina Ahmetaj-Shala, PhDNicholas S. Kirkby, PhDCardiothoracic PharmacologyVascular BiologyNational Heart and Lung InstituteImperial CollegeLondon, UKRebecca Knowles, MDThe William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen MaryUniversity of LondonLondon, UKMalak Al’Yamani, MScSara Mazi, MResCardiothoracic PharmacologyVascular BiologyNational Heart and Lung InstituteImperial CollegeLondon, UKKing Fahad Cardiac CenterKing Saud UniversityRiyadh, Saudi ArabiaZhen Wang, PhDMRC Clinical SciencesImperial College LondonNitric Oxide Signalling GroupHammersmith HospitalLondon, UKArthur T. Tucker, PhDThe William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen MaryUniversity of LondonLondon, UKLouise S. Mackenzie, PhDSchool of Life and Medical SciencesUniversity of HertfordshireHatfield, UKPaul C.J. Armstrong, PhDThe William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen MaryUniversity of LondonLondon, UKRolf M. Nüsing, PhDInstitute of Clinical PharmacologyJohann Wolfgang Goethe-UniversityFrankfurt, GermanyJames A. P. Tomlinson, MD, PhDMRC Clinical SciencesImperial College LondonNitric Oxide Signalling GroupHammersmith HospitalLondon, UKTimothy D. Warner, PhDThe William Harvey Research InstituteBarts and the London School of Medicine and DentistryQueen MaryUniversity of LondonLondon, UKJames Leiper, PhDMRC Clinical SciencesImperial College LondonNitric Oxide Signalling GroupHammersmith HospitalLondon, UKJane A. Mitchell, PhDCardiothoracic PharmacologyVascular BiologyNational Heart and Lung InstituteImperial CollegeLondon, UKDisclosuresDr Mitchell is a member of the scientific advisory board for Antibe Therapeutics. Drs Mitchell and Warner have been expert witnesses for cases associated with Pfizer products. The other authors report no conflicts.References1. Ahmetaj-Shala B, Kirkby NS, Knowles R, Al’Yamani M, Mazi S, Wang Z, Tucker AT, Mackenzie L, Armstrong PC, Nüsing RM, Tomlinson JA, Warner TD, Leiper J, Mitchell JA. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of cardiovascular side effects associated with anti-inflammatory drugs.Circulation. 2015; 131:633–642. doi: 10.1161/CIRCULATIONAHA.114.011591.LinkGoogle Scholar2. Surdacki A, Martens-Lobenhoffer J, Wloch A, Marewicz E, Rakowski T, Wieczorek-Surdacka E, Dubiel JS, Pryjma J, Bode-Böger SM. Elevated plasma asymmetric dimethyl-l-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis.Arthritis Rheum. 2007; 56:809–819. doi: 10.1002/art.22424.CrossrefMedlineGoogle Scholar3. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, Leiper J, Cooke JP. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.Circulation. 2013; 128:845–853. doi: 10.1161/CIRCULATIONAHA.113.003602.LinkGoogle Scholar4. Kirkby NS, Lundberg MH, Chan MV, Vojnovic I, Solomon AB, Emerson M, Mitchell JA, Warner TD. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.Proc Natl Acad Sci U S A. 2013; 110:15782–15787. doi: 10.1073/pnas.1218880110.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Bindu S, Mazumder S and Bandyopadhyay U (2020) Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective, Biochemical Pharmacology, 10.1016/j.bcp.2020.114147, 180, (114147), Online publication date: 1-Oct-2020. Kirkby N, Tesfai A, Ahmetaj‐Shala B, Gashaw H, Sampaio W, Etelvino G, Leão N, Santos R and Mitchell J (2016) Ibuprofen arginate retains eNOS substrate activity and reverses endothelial dysfunction: implications for the COX‐2/ADMA axis, The FASEB Journal, 10.1096/fj.201600647R, 30:12, (4172-4179), Online publication date: 1-Dec-2016. October 27, 2015Vol 132, Issue 17 Advertisement Article InformationMetrics © 2015 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.115.017260PMID: 26503755 Originally publishedOctober 27, 2015 PDF download Advertisement SubjectsEndothelium/Vascular Type/Nitric Oxide